2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - Hall C
This is a strong session of new therapies for Myelofibrosis and 1 for Mast cell disease. If other clinical MPN session has 1 MF oral trial could move it here, and swap out the SM trial to theirs if makes sense.<br /><br />Sugested Title: <span style="caret-color: #000000; color: #000000; font-family: Aptos, Aptos_EmbeddedFont, Aptos_MSFontService, Calibri, Helvetica, sans-serif; font-size: 14.666667px; font-style: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration: none; display: inline !important; float: none;">MF and SM: Emerging Targets and Treatment Strategies</span>
Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Monoclonal Antibody Therapy, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, MPN, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence
PAPER

414 A patient preferences-controlled study of allogeneic hematopoietic cell transplantation versus best available non-transplant therapies in patients with high-risk myelofibrosis (ALLO-BAT study)

Vikas Gupta, MD FRCP, FRCPath, Shanee Chung, MBChB, FRACP, FRCPA, FRCPC2, James A. Kennedy, MD PhD3, Mary Lynn Savoie, MD, FRCPC4, Jose-Mario Capo-Chichi, MD, PhD5, Etienne Mahe, MD, FRCPC, FCAP6, Lorena Maffra7, Kelly Foley8, Eshetu Atenafu9, Jaime Claudio, PhD10, Merrill Pierce11, Auro Viswabandya, MBBS MD DM12, Sonia Cerquozzi, MD, FRCPC13
1 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
2 Leukemia/BMT Program of British Columbia, Vancouver, British Columbia, Canada
3 Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
4 Tom Baker Cancer Centre, Calgary, Alberta, Canada
5 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
6 Tom Baker Cancer Centre, Calgary, Alberta, Canada
7 Princess Margaret Cancer Centre, Toronto, Canada
8 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
9 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
10 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
11 Canadian MPN Research Foundation, Toronto, Ontario, Canada
12 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
13 Tom Baker Cancer Centre, Calgary, Alberta, Canada

Background
The efficacy of allogeneic hematopoietic cell transplantation (HCT) vs. best available non-transplant therapies (BAT) has never been investigated prospectively in myelofibrosis (MF). Randomized trials (RCT) are not logistically feasible due to rarity. A retrospective study from Princess Margaret showed that apprx. 50% of MF patients with an indication for HCT, and available donors choose BAT (Smith E, et al, TCT, 2021). Therefore, we hypothesized that a patient preference-controlled study may provide an alternative to RCT to study the efficacy of HCT vs. BAT. The primary objectives of this multi-center study are a) to evaluate the feasibility of patient preference-controlled study design by characterizing the proportion of patients choosing HCT vs. BAT and b) describe the patient factors as well as their goals/values and attitudes that impact treatment preferences. Secondary objectives are to compare the survival, health-related quality of life (HRQOL; EORTC-QLQ-C30, FACT-BMT) and patient reported outcomes (PRO; MPN-SAF-TSSv4.0, PGIC).

Methods
Key eligibility criteria: adults age 70 years or below with a diagnosis of primary or secondary MF in chronic phase, and agreeable to donor search. High-risk MF was defined by molecular integrated risk stratification as: MIPSS-70 plus v2.0 high/very-high or MIPSS70 high-risk (when cytogenetics results not available) or presence of TP53 mutation. Patients on ruxolitinib at study entry, who met criteria of ruxolitinib failure (Gupta V, et al JCO OP, 2020) were excluded. The study included 2 stages: registration and study arm allocation. Maximum time allowed between registration and study arm allocation was 6 months. All registered patients had donor searches initiated. The selection between HCT or BAT was made by the patient in consultation with their physician. All the patients completed a study specific patient-preference survey.  Attitude to treatment was studied by a preference-controlled scale (Degner LF, et al J Clin Epidemiology, 1992). The study arm allocation was confirmed by a steering committee (SC) which met monthly to review eligibility criteria including disease status, co-morbidities, pathology, molecular and cytogenetics, donor availability and patient preferences; and accordingly allocated the study arm (HCT or BAT). The study arm allocation date was considered as the index date for all outcome analysis.

Results
Sixty-four patients were registered in this study, and 46 patients (72%) were allocated to study arms: HCT, 28 (61%); BAT 18 (39%). 18 patients were deemed ineligible for arm allocation due to: failure to meet protocol definition of high-risk (n=4), progression to accelerated phase or ruxolitinib failure (n=5), organ failure (n=3) and misc. (n=6). Median age was 64 years (range 30-70), and 40/46 (87%) were ruxolitinib naïve. High-risk MF included: MIPSS70v2.0 high or very-high (n=28), MIPSS70 high (n=14) and TP53 mutated (n=4). There was no difference between baseline patient or disease characteristics, and donor availability between study arms. In particular, no differences in self-reported ethnicity (73% Caucasian), education, employment status, living arrangements, household income, symptoms or HRQOL were observed. Using preference-controlled scale, 49% of patients expressed a preference towards shared decision, 11% wanted their doctor to make the decision and 40% wanted to make the final decision after considering their physician opinion. All patients assigned to HCT arm underwent HCT. Ruxolitinib was most commonly used BAT. The median follow-up at the data cut off was 18 months (range 2-61). Overall survival at 18 months in HCT and BAT arms was 82% (95% CI 57-93) and 87% (95% CI 55-97), respectively (p=0.50). PRO and HR-QOL showed worsening of physical and social functioning in HCT arm with nadir at 3-6 months, that improved back to baseline around 12 months, and at that time point was comparable to BAT patients.

Conclusions
We demonstrate the feasibility of a patient-preference controlled study design as a viable option for evaluating the efficacy of HCT vs. BAT for high-risk MF. Thirty-nine percent of high-risk MF patients with available donors preferred BAT over HCT. The majority of patients (49%) expressed a preference for shared decision making. No difference in survival was observed between HCT and BAT arms at 18 months, with an ongoing long-term follow up. (NCT 04217356, funded by MPN Research Foundation, Chicago, USA).   

 

Vikas Gupta, MD FRCP, FRCPath: Daichii/Daichii Sankyo - Honoraria; GlaxoSmithKline - Honoraria; Incyte Corporation - Honoraria; Bristol Myers Squibb/Celgene - Honoraria; Pfizer - Honoraria; Novartis - Honoraria; Sumitomo - Honoraria; AbbVie - Research Funding; Pfizer - Consultancy (Includes expert testimony); Daichii/Daichii Sankyo - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Sumitomo - Consultancy (Includes expert testimony); GlaxoSmithKline - Consultancy (Includes expert testimony); Daiichi - Membership on a Board/Advisory Committee